AI Uses in Biotechnology [5 Case Studies] [2026]
Artificial Intelligence is reshaping the landscape of biotechnology by accelerating discovery, reducing research costs, and unlocking insights that were previously out of reach. From drug design to protein modeling and synthetic biology, AI is driving innovation across every corner of the life sciences industry. This article explores five real-world case studies that demonstrate the transformative power of AI in biotechnology. Companies like Insilico Medicine, DeepMind, Recursion Pharmaceuticals, Ginkgo Bioworks, and BenevolentAI are at the forefront, using cutting-edge machine learning models to solve complex biological challenges. These examples showcase how AI is reducing drug discovery timelines from years to weeks, predicting protein structures with near-experimental accuracy, and automating biological design at industrial scales. Curated by DigitalDefynd, this in-depth analysis serves as a guide to understanding how AI is revolutionizing biotechnology in practice—not just theory.
5 Case Studies of AI Use in Biotechnology [2026]
1. AI-Powered Drug Discovery at Insilico Medicine
Challenge
Insilico Medicine, a biotechnology company founded in 2014, set out to address one of the most persistent and costly challenges in the pharmaceutical industry—accelerating the drug discovery process. Traditional drug discovery is a lengthy, expensive, and failure-prone endeavor, often taking more than 10 years and costing over $2.6 billion to bring a single drug to market. The inefficiencies stem from the complexity of identifying viable drug targets, designing promising molecules, and predicting toxicity or efficacy early in the pipeline.
Furthermore, conventional methods depend heavily on trial-and-error experimentation, with researchers needing to manually screen vast compound libraries and perform multiple rounds of lab testing. This slow pace significantly delays treatment availability, especially for diseases with urgent unmet medical needs. Insilico Medicine recognized that solving these inefficiencies would require rethinking the early stages of drug discovery using cutting-edge AI and machine learning technologies to automate and optimize key decisions.
Solution
a. Target Identification: Insilico uses deep learning models to analyze vast biomedical datasets and predict novel disease targets. These models can integrate genomic, proteomic, and transcriptomic data to pinpoint previously unrecognized biological markers associated with diseases.
b. Molecule Generation: Their proprietary AI platform, Chemistry42, designs novel molecular structures using generative adversarial networks (GANs). These algorithms can create entirely new chemical compounds optimized for drug-likeness, binding affinity, and synthesizability.
c. Preclinical Validation: Insilico uses predictive AI tools to simulate how new drug candidates will behave in the body, evaluating their absorption, distribution, metabolism, and excretion (ADME) profiles. It reduces the number of compounds that fail in preclinical testing due to poor pharmacokinetics.
d. Automated Synthesis Planning: The AI platform also generates step-by-step synthetic pathways for each designed molecule, accelerating laboratory synthesis. It allows chemists to test promising compounds faster, with fewer resources.
e. Clinical Trial Prediction: Insilico’s AI algorithms can forecast clinical trial outcomes by simulating how a candidate drug might interact with a disease population. These simulations improve trial design and patient recruitment strategies, reducing time-to-trial and increasing the likelihood of success.
f. End-to-End Platform: The company integrates all stages—from discovery to preclinical development—into one AI-enabled platform. This unified pipeline minimizes handoff delays, automates repetitive research tasks, and enables faster iteration cycles.
Result
Insilico Medicine’s AI-driven platform has revolutionized drug discovery timelines. In 2021, the company announced it had developed a novel preclinical drug candidate for idiopathic pulmonary fibrosis (IPF) in just 30 days from target identification to lead molecule generation—a milestone that traditionally takes years. This achievement demonstrated the potential for AI to dramatically shorten drug development cycles and reduce costs.
By integrating AI across all phases of discovery and preclinical development, Insilico has enhanced precision and productivity, achieving better hit rates for drug candidates. Their platform has been licensed by several pharmaceutical giants, including Pfizer and Fosun Pharma, indicating strong industry validation. Additionally, Insilico secured over $400 million in funding to scale its operations, highlighting investor confidence in AI’s role in transforming biotech innovation. Insilico’s success illustrates how AI can de-risk early R&D, reduce experimental failures, and democratize access to advanced drug design capabilities.
Related: AI for Pharma & Biotech Courses
2. DeepMind’s AlphaFold Transforming Protein Structure Prediction
Challenge
For decades, one of the most significant challenges in biotechnology and molecular biology was the “protein folding problem.” Scientists have long known that a protein’s 3D shape determines its biological function, yet predicting that shape from its amino acid sequence proved extraordinarily difficult. Traditional experimental methods like X-ray crystallography, cryo-electron microscopy, and nuclear magnetic resonance spectroscopy are accurate but extremely time-consuming, costly, and labor-intensive. Determining the structure of a single protein could take months or even years.
The complexity arises because proteins can fold into countless possible conformations, and predicting the most stable one involves solving enormous mathematical and biochemical puzzles. Incomplete structural data hindered progress in understanding diseases, developing new drugs, and engineering enzymes for industrial use. To address this longstanding scientific bottleneck, DeepMind, a subsidiary of Alphabet, set out to create an AI system capable of accurately predicting protein structures at a scale and speed that traditional methods could never achieve.
Solution
a. AI-Based Prediction Model: DeepMind developed AlphaFold, a deep learning system that uses advanced neural networks to predict the 3D structures of proteins directly from their amino acid sequences. The model was trained on public protein databases, learning how amino acids fold and interact to form complex structures.
b. Attention Mechanisms: AlphaFold employs attention-based architectures similar to those used in natural language processing models. It allows the AI to understand spatial relationships within the amino acid sequence and predict interatomic distances and angles with remarkable precision.
c. Integration of Physical and Biological Constraints: The system integrates biological knowledge and physical laws governing protein folding, ensuring that the predictions are biochemically realistic. This hybrid approach blends data-driven learning with fundamental science principles.
d. Benchmark Performance: In the 2020 CASP14 (Critical Assessment of Structure Prediction) competition, AlphaFold achieved an unprecedented median Global Distance Test (GDT) score of 92.4 out of 100, indicating near-experimental accuracy. This marked a historic leap in computational biology, effectively solving the protein folding problem that had persisted for over 50 years.
e. Public Database Collaboration: Following its success, DeepMind partnered with the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) to release the AlphaFold Protein Structure Database. This open-access platform provides predicted structures for over 200 million proteins across nearly all known organisms, making it one of the largest scientific contributions in modern biology.
f. Widespread Applications: Researchers globally are now using AlphaFold’s predictions to accelerate drug discovery, understand antibiotic resistance, and design enzymes for environmental applications, such as plastic degradation and biofuel production.
Result
AlphaFold’s introduction has transformed biotechnology research. By providing near-experimental accuracy in minutes rather than months, it has dramatically reduced the time and cost associated with structural biology. Pharmaceutical companies and academic institutions now rely on AlphaFold data to identify potential drug targets, design therapeutics, and explore disease mechanisms at a molecular level. The AlphaFold database has been accessed millions of times by scientists worldwide, catalyzing discoveries in cancer biology, neuroscience, and microbiology. Researchers have used its predictions to uncover protein structures related to malaria parasites, SARS-CoV-2, and antibiotic-resistant bacteria, directly influencing vaccine design and drug development strategies.
In 2022, DeepMind expanded AlphaFold’s database to cover nearly every protein known to science, creating what many experts describe as a new “periodic table of life.” By solving a problem once considered unsolvable, AlphaFold has become one of the most important scientific breakthroughs of the century, reshaping how biotechnology, medicine, and synthetic biology advance in the AI era.
Related: Impact of AI on UX/UI Design
3. Recursion Pharmaceuticals Using AI for Phenotypic Screening
Challenge
Drug discovery often begins with identifying how potential compounds affect cells, a process known as phenotypic screening. Traditionally, this approach involves manually analyzing images of cells treated with various compounds to detect changes in shape, structure, or behavior that suggest therapeutic effects. However, this method is labor-intensive, prone to human bias, and limited in scale. The complexity of interpreting cellular morphology makes it difficult to systematically link visual patterns to molecular mechanisms or clinical outcomes.
Recursion Pharmaceuticals, a biotechnology company based in Salt Lake City, recognized that this bottleneck severely restricted the speed and scalability of drug discovery. With over 7,000 rare diseases lacking approved treatments, the company aimed to dramatically increase the efficiency and scope of phenotypic screening. Their mission was to use artificial intelligence to automate cellular image analysis and identify drug candidates faster, more accurately, and across a broader range of diseases than traditional methods allowed.
Solution
a. Automated High-Content Imaging: Recursion built robotic laboratory systems that perform high-throughput experiments, exposing human cells to thousands of chemical and genetic perturbations. These experiments generate millions of high-resolution cellular images under varied conditions.
b. AI-Driven Image Analysis: The company developed deep learning models to analyze these images and identify phenotypic changes that would be nearly impossible for the human eye to detect. These models classify cellular morphologies, detect subtle patterns, and map phenotypic fingerprints associated with specific diseases.
c. Massive Data Generation: Recursion has created one of the world’s largest biological image datasets, with over 20 petabytes of data. Their AI models continuously learn from this data, improving accuracy and making connections across different diseases, cell types, and treatment responses.
d. Phenomic Mapping: Using AI, Recursion constructs phenomic maps that visually cluster similar cellular responses. These maps help scientists identify potential drug repurposing opportunities or new targets by recognizing patterns that indicate therapeutic potential.
e. Closed-Loop Learning: The AI platform uses a closed-loop approach, where model predictions guide new experiments, and the resulting data further refine the algorithms. This iterative cycle accelerates the discovery process and ensures continuous model improvement.
f. Cross-Disease Applications: The platform is not limited to a single therapeutic area. It has been applied to discover drug candidates for oncology, inflammation, fibrosis, infectious diseases, and rare genetic conditions.
Result
Recursion Pharmaceuticals has revolutionized phenotypic drug discovery by replacing subjective image interpretation with automated, AI-powered analysis. Their platform enables the screening of over 1 million compounds per week, compared to traditional systems that typically process far fewer. This scale has allowed Recursion to build one of the most diverse and powerful phenotypic datasets in biotechnology.
The company has advanced over 40 drug programs internally and through partnerships, including collaborations with Bayer and Roche. One of their most notable successes includes the discovery of potential treatments for cerebral cavernous malformations (CCMs), a rare genetic condition with no FDA-approved therapy. Using its AI platform, Recursion identified and progressed compounds to preclinical and early clinical trials in a fraction of the usual time. Recursion’s AI-first approach has attracted significant investment, raising over $1 billion and going public in 2021. The company continues to expand its capabilities, integrating more biological modalities such as transcriptomics and proteomics into its AI models.
Related: Impact of AI on Supply Chain Management
4. Ginkgo Bioworks Leveraging AI for Synthetic Biology Design
Challenge
Synthetic biology involves designing and engineering organisms to perform new functions, such as producing pharmaceuticals, biofuels, fragrances, or food ingredients. However, biological systems are inherently complex, and designing genetic modifications that yield consistent, scalable results is a major challenge. Traditional methods for modifying DNA sequences rely on trial and error, which is time-consuming, resource-intensive, and limited by the ability to test only a small number of variations at a time.
Ginkgo Bioworks, a Boston-based synthetic biology company, set out to industrialize organism design by integrating AI and automation. Their goal was to program cells as easily as software engineers write code, enabling rapid design and testing of custom microbes. However, scaling this vision required overcoming massive hurdles—engineering biology at scale involves sifting through billions of possible DNA combinations, optimizing for performance, cost, safety, and regulatory compliance, all while working with live biological systems prone to variability.
Solution
a. AI-Enabled Genetic Design: Ginkgo uses machine learning algorithms to design genetic sequences that instruct microorganisms to perform specific functions, such as producing a target molecule. The AI evaluates gene pathways and predicts how genetic edits will impact cell behavior and output.
b. Automated Foundry Platform: The company built a robotic “foundry” that can automatically synthesize, assemble, and test thousands of genetic constructs simultaneously. This closed-loop system integrates AI models with real-time experimental data, accelerating the build-test-learn cycle.
c. High-Throughput Screening: Ginkgo’s AI models identify the most promising genetic variants by analyzing massive datasets from DNA sequencing, proteomics, and metabolomics. It ensures that only the most effective designs move forward, reducing the time and cost of strain development.
d. Knowledge Graphs and Data Integration: The company uses AI to build knowledge graphs that connect biological functions, genetic parts, and experimental outcomes. It allows the platform to generalize learnings from one organism or project to another, improving predictive accuracy.
e. Partner-Focused Model: Ginkgo collaborates with pharmaceutical, agriculture, and consumer goods companies to develop customized biological solutions. Its AI and foundry are used to engineer microbes for producing ingredients like therapeutic proteins, plant-based meat flavorings, and industrial enzymes.
f. Biosecurity Integration: Ginkgo also applies AI to screen designs for safety and compliance, flagging sequences that may pose biosecurity risks or violate regulatory standards.
Result
Ginkgo Bioworks has redefined what is possible in synthetic biology by combining AI with automation and biology. The company has completed over 500 million base pairs of engineered DNA and run billions of automated tests. Its platform has powered projects ranging from producing rose-scented compounds for perfumes to developing probiotics for gut health and, more recently, contributing to COVID-19 response efforts through rapid test development. Its partnerships include major names such as Bayer, Moderna, and Roche, enabling wide-scale impact across industries. For instance, Ginkgo helped Bayer develop microbes that enhance crop nitrogen fixation, reducing dependence on synthetic fertilizers. In another partnership, it collaborated with Aldevron to optimize the manufacturing of mRNA for therapeutic applications.
The company has raised over $1.6 billion in funding and went public in 2021 through a SPAC merger valued at $17.5 billion. Today, Ginkgo operates one of the largest foundries in the world for biological engineering. By embedding AI into every stage of the design-build-test cycle, Ginkgo Bioworks has created a powerful, scalable engine for biological innovation.
Related: Why & How to Study Artificial Intelligence
5. BenevolentAI Accelerating Target Identification for Drug Development
Challenge
Identifying the right biological target is one of the most critical and difficult steps in the drug discovery process. A poor choice of target often leads to failure in later stages, resulting in wasted resources and delays in bringing effective treatments to patients. Traditionally, target identification relies heavily on existing literature, expert opinions, and slow-moving lab-based experimentation. These methods can overlook hidden connections within the vast and ever-growing volume of biomedical data, making them inefficient and limited in scope.
BenevolentAI, a London-based biotechnology company, recognized that unlocking insights buried in unstructured scientific data could significantly enhance drug discovery. The company’s challenge was to use artificial intelligence to analyze massive, complex datasets—including scientific literature, clinical trial results, genomic data, and biomedical research—faster and more comprehensively than human researchers ever could. By doing so, BenevolentAI aimed to identify novel disease targets and potential treatment candidates that may otherwise remain undiscovered.
Solution
a. AI-Powered Knowledge Graphs: BenevolentAI built a proprietary knowledge graph that integrates and connects millions of data points across scientific papers, patents, clinical trials, genomic datasets, and biological ontologies. This graph enables AI algorithms to identify relationships between diseases, genes, and potential drug targets.
b. Natural Language Processing (NLP): The company uses advanced NLP techniques to extract insights from unstructured text in biomedical literature. These tools read and interpret complex scientific documents, allowing the platform to stay updated with the latest research findings in real time.
c. Hypothesis Generation Engine: The AI system continuously scans and analyzes the knowledge graph to propose novel, testable hypotheses about disease mechanisms and drug targets. These hypotheses are ranked by relevance and strength of evidence, guiding scientists toward the most promising leads.
d. Target Validation: Once a potential target is identified, BenevolentAI combines in silico modeling and wet-lab experimentation to validate the target’s role in disease pathways. This integrated approach ensures a higher success rate before progressing to drug development stages.
e. Partnership Integration: BenevolentAI collaborates with leading pharmaceutical companies like AstraZeneca and Novartis. Their AI platform supports partner research programs by uncovering novel targets for complex diseases, including chronic kidney disease, idiopathic pulmonary fibrosis, and systemic lupus erythematosus.
f. Therapeutic Area Focus: The company applies its AI pipeline across multiple disease areas, including neurology, oncology, and immunology. Its flexible platform is capable of rapidly pivoting based on emerging research or global health priorities.
Result
BenevolentAI has demonstrated real-world success in improving drug discovery outcomes using artificial intelligence. One of the company’s most widely recognized achievements came during the COVID-19 pandemic, when its AI platform identified baricitinib—a drug originally approved for rheumatoid arthritis—as a potential treatment for COVID-19. This recommendation was made early in the pandemic and later validated in clinical trials, with baricitinib becoming part of treatment protocols under emergency use authorization by the FDA.
The company’s AI-driven approach has significantly reduced the time needed for target identification, cutting the early discovery phase from years to months. Its ongoing partnership with AstraZeneca has resulted in multiple target discoveries, advancing the pipeline for diseases with high unmet needs. BenevolentAI went public in 2022 through a merger valued at over $1.1 billion, reinforcing investor confidence in its technology and strategy. Its ability to mine hidden insights from massive biomedical datasets has positioned it as a leader in AI-enabled drug discovery. By merging scientific expertise with machine intelligence, BenevolentAI continues to accelerate the path from data to therapeutics, offering new hope for tackling complex and previously untreatable diseases.
Conclusion
The integration of AI into biotechnology has moved well beyond experimentation—it is now a core driver of innovation, efficiency, and scalability. These five case studies from Insilico Medicine, DeepMind, Recursion Pharmaceuticals, Ginkgo Bioworks, and BenevolentAI illustrate how AI is redefining what is possible in areas like drug discovery, protein structure prediction, phenotypic screening, synthetic biology, and therapeutic target identification. With tangible outcomes such as FDA-approved treatments, accelerated preclinical timelines, and billion-dollar valuations, these companies are setting new standards for the biotech industry. As more organizations adopt AI-driven approaches, the future of biotechnology looks faster, smarter, and more precise. This article, compiled by DigitalDefynd, aims to provide actionable inspiration for stakeholders across academia, industry, and government who are navigating the next wave of life sciences innovation through AI.
